LY3561774 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dyslipidemias
Conditions
Dyslipidemias
Trial Timeline
Nov 30, 2020 → May 17, 2022
NCT ID
NCT04644809About LY3561774 + Placebo
LY3561774 + Placebo is a phase 1 stage product being developed by Eli Lilly for Dyslipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT04644809. Target conditions include Dyslipidemias.
What happened to similar drugs?
6 of 6 similar drugs in Dyslipidemias were approved
Approved (6) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05256654 | Phase 2 | Completed |
| NCT04644809 | Phase 1 | Completed |
Competing Products
15 competing products in Dyslipidemias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY3202328 + Placebo + Atorvastatin + Simvastatin | Eli Lilly | Phase 1 | 29 |
| Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mg | Yuhan | Approved | 43 |
| LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC | Eli Lilly | Phase 1 | 29 |
| LY3885125 + Placebo | Eli Lilly | Phase 1 | 21 |
| LY3561774 + Placebo | Eli Lilly | Phase 2 | 35 |
| LY2484595 + Placebo + Atorvastatin | Eli Lilly | Phase 2 | 35 |
| Atorvastatin + Atorvastatin | Pfizer | Approved | 43 |
| Atorvastatin | Pfizer | Approved | 43 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 43 |
| Vupanorsen + Placebo | Pfizer | Phase 2 | 35 |
| Atorvastatin | Pfizer | Approved | 43 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 43 |
| GWP42003 + GWP42003 + GWP42004 + Placebo | Jazz Pharmaceuticals | Phase 2 | 32 |
| ARO-APOC3 | Arrowhead Pharmaceuticals | Phase 2 | 32 |
| ARO-ANG3 + sterile normal saline (0.9% NaCl) | Arrowhead Pharmaceuticals | Phase 1 | 26 |